Algernon Pharmaceuticals Receives U.S. FDA Clearance for Phase 2b/3 Ifenprodil Human Study

Algernon Pharmaceuticals Receives U.S. FDA Clearance for Phase 2b/3 Ifenprodil Human Study

 

 

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with major news for the company that they have received clearance from the U.S. FDA for its multinational Phase 2b/3 study of Ifenprodil as a potential treatment for COVID-19.

Moreau talks about how big this milestone is for the company and how the study is to be conducted.

Share via
Copy link
Powered by Social Snap